“GLP-1 Agonists Market Size, Target Population, Competitive Landscape & Market Forecast – 2034”
DelveInsight’s report projects strong growth in the GLP-1 Agonists market across the US, EU4, UK, and Japan through 2034, driven by rising diabetes and obesity cases. Key players include Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, Veru Inc., Viking Therapeutics, Terns Pharmaceuticals, Eccogene, Pfizer, and Boehringer Ingelheim, with pipeline drugs like Saxenda, VK2735, TERN-601, ECC5004, orforglipron, survodutide, danuglipron, and retatrutide fueling market expansion.
DelveInsight’s “GLP-1 Agonists Market Size, Target Population, Competitive Landscape & Market Forecast – 2034” report delivers a comprehensive analysis of the GLP-1 Agonists market, covering historical and forecasted patient pools, current treatment practices, emerging drugs, and market size trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Key Takeaways
-
Market size projection: As per DelveInsight’s analysis, the total market size of GLP-1 agonists in the 7MM is expected to surge significantly by 2034, with the market anticipated to grow at a significant CAGR throughout the forecast period.
-
Patient population data: The report provides the total GLP-1 agonists potential pool, indicating substantial eligible patient populations for both type 2 diabetes and obesity indications across the seven major markets.
-
Key GLP-1 companies: Leading GLP-1 agonist companies, such as Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, Veru Inc., Viking Therapeutics, Inc., Terns Pharmaceuticals, Inc., Eccogene, Pfizer, and Boehringer Ingelheim, are developing novel GLP-1 agonists that can be available in the market in the coming years.
-
GLP-1 Pipeline assets: Some of the key GLP-1 agonists in the pipeline include Saxenda, Enobosarm, VK2735, TERN-601, ECC5004, orforglipron, survodutide, danuglipron, and retatrutide, among others.
-
In April 2025, Northstrive Biosciences announced it received preliminary feedback from the FDA on its planned Type B pre-IND meeting, supporting the advancement of its EL-22 program in combination with GLP-1 receptor agonists toward a Phase 2 clinical trial.
-
In August 2025, the FDA warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, or retatrutide that are falsely labeled “for research purposes only”, highlighting ongoing concerns about the proliferation of unregulated GLP-1 medications in the market.
-
In May 2025, Eli Lilly withdrew its FDA application for Zepbound (tirzepatide) for treating heart failure with preserved ejection fraction (HFpEF) in patients with obesity.
-
In January 2025, Ozempic (semaglutide) received FDA approval for a new indication: reducing the risk of kidney disease worsening, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. This makes Ozempic the first GLP-1 receptor agonist approved for kidney disease prevention.
-
In November 2024, the FDA approved Amneal’s generic version of exenatide injection (Byetta), marking the first generic GLP-1 receptor agonist available in the market.
Discover recent advancements in the GLP-1 Agonists landscape @ GLP-1 Agonists Recent Developments.
GLP-1 Drugs Market Dynamics
The GLP-1 agonists market represents one of the most dynamic and rapidly evolving segments in the pharmaceutical industry, driven by the escalating global diabetes epidemic and expanding obesity prevalence. The current market demonstrates robust momentum, with regulatory bodies having approved multiple GLP-1 receptor agonists, including TRULICITY (dulaglutide), BYETTA/BYDUREON (exenatide), VICTOZA (liraglutide), OZEMPIC/WEGOVY/RYBELSUS (Semaglutide), and MOUNJARO/ZEPBOUND (tirzepatide), establishing a strong foundation for market expansion through 2034.
Market momentum is primarily fueled by the increasing recognition of GLP-1 agonists’ dual therapeutic benefits in managing both glycemic control and weight management. These medications work by imitating the action of the natural hormone glucagon-like peptide-1, which helps regulate glucose levels in the blood while providing additional benefits, including increased glucose uptake in muscles, decreased glucose production in the liver, neuroprotection, and increased satiety through direct actions on the hypothalamus. In type 2 diabetes, GLP-1 agonists trigger the pancreas to release more insulin, slow digestion to decrease blood sugar spikes, and reduce food intake through appetite suppression, often resulting in significant weight loss.
The GLP-1 drugs clinical development landscape showcases extensive pipeline activity across major pharmaceutical companies, with innovative candidates advancing through various phases of development. The GLP-1 drug pipeline includes both traditional injectable formulations and next-generation oral formulations, providing patients and healthcare providers with flexible therapeutic approaches. This diversification in delivery methods addresses current treatment gaps and aims to improve patient compliance and treatment outcomes.
The GLP-1 agonist competitive landscape is characterized by intense industry participation, with established players like Novo Nordisk, Eli Lilly, and AstraZeneca leading market share, while emerging companies contribute innovative approaches to GLP-1 modulation. Strategic approaches vary from developing novel formulations and delivery systems to exploring combination therapies and expanding therapeutic indications beyond diabetes management.
Current challenges include pricing pressures, reimbursement complexities, and manufacturing capacity constraints to meet growing demand. However, these challenges are offset by significant opportunities, including expanding indications for cardiovascular protection, potential applications in neurodegenerative diseases, and growing acceptance among healthcare providers and patients. The future outlook remains exceptionally positive, with growth drivers including increasing diabetes prevalence, rising obesity rates, expanding clinical evidence for cardiovascular benefits, and continued innovation in drug delivery systems expected to sustain market expansion throughout the forecast period.
Download the GLP-1 Agonists Market report to understand which factors are driving the market @ GLP-1 Agonists Market Trends.
GLP-1 Drugs Targeted Patient Pool
The GLP-1 agonists epidemiological landscape encompasses a substantial patient population across the seven major markets (7MM), including the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. Type 2 diabetes mellitus, which accounts for over 85% of all diabetes cases worldwide, represents the primary indication driving market demand. As of 2021, approximately 537 million adults were living with diabetes globally, with about 1.4 million new cases of diabetes diagnosed in the United States alone each year, indicating a continuously expanding patient population requiring therapeutic intervention.
The GLP-1 drugs patient pool segmentation reveals distinct patterns across age demographics, with type 2 diabetes being more prevalent among older adults, particularly those over 65 years, where the prevalence exceeds 25%. This demographic trend suggests a growing patient pool as global populations age, further supporting market expansion projections. The total cases in selected indications encompass both type 2 diabetes and obesity, with substantial overlap between these conditions creating additional therapeutic opportunities for GLP-1 agonists.
The total eligible patient pool demonstrates significant potential across all seven major markets, with varying prevalence rates and treatment penetration levels creating distinct opportunities in different geographic regions. The total treated cases currently represent a fraction of the eligible population, indicating substantial room for market growth as awareness increases, treatment guidelines evolve, and access improves.
Furthermore, the geographic segmentation across the 7MM reveals distinct market characteristics, with the United States representing the largest market opportunity due to high diabetes prevalence and favorable reimbursement environments, while European markets show steady growth patterns driven by expanding clinical evidence and regulatory approvals. Japan presents unique opportunities with its aging population and increasing diabetes prevalence, contributing to the overall market expansion projected throughout the forecast period from 2020 to 2034.
Discover evolving trends in the GLP-1 Agonists patient pool forecasts @ GLP-1 Agonists Epidemiology Analysis.
Key GLP-1 Companies and Treatment Market
The GLP-1 agonist clinical and regulatory landscape reflects a mature and rapidly evolving therapeutic area with multiple approved treatment options and robust pipeline activity. Current treatment options include both injectable and oral formulations, with regulatory bodies having approved GLP-1 receptor agonists for glycemic control including dulaglutide (subcutaneous), exenatide injectable solution subcutaneous, exenatide injectable suspension subcutaneous, liraglutide subcutaneous, liraglutide/insulin degludec, lixisenatide/insulin glargine, semaglutide (oral and subcutaneous), and tirzepatide as a dual GIP/GLP-1 receptor agonist. Additionally, regulatory bodies have approved specific GLP-1 agonists for weight loss, including semaglutide subcutaneous and liraglutide subcutaneous.
The GLP-1 clinical pipeline activity spans multiple development phases, with companies pursuing diverse therapeutic approaches and novel delivery mechanisms. Key players include Novo Nordisk (developing various semaglutide formulations), Eli Lilly and Company (orforglipron and retatrutide), Boehringer Ingelheim (survodutide), Pfizer (danuglipron), Viking Therapeutics (VK2735), Terns Pharmaceuticals (TERN-601), and Eccogene (ECC5004), among others. These companies represent various stages of clinical development, from early-phase innovations to late-stage candidates approaching regulatory approval.
Market positioning of these therapies varies based on their mechanism of action, development status, and clinical applications. Established products like TRULICITY, OZEMPIC, and MOUNJARO have secured strong positions in current treatment paradigms for type 2 diabetes management, while emerging candidates aim to address unmet needs through improved efficacy profiles, reduced side effects, or enhanced convenience through novel delivery systems.
Development milestones continue to shape the competitive landscape, with recent regulatory approvals including generic versions of established therapies and expanding indications for cardiovascular protection representing significant market developments. Commercial arrangements, including licensing deals and strategic collaborations, are becoming increasingly important as companies seek to leverage complementary expertise and accelerate development timelines while managing the substantial investment required for successful GLP-1 agonist development and commercialization.
Discover which companies are innovating in the GLP-1 Agonists landscape @ GLP-1 Agonists Competitive Landscape.
Conclusion
The GLP-1 agonists market represents a transformative opportunity in diabetes and obesity management, with DelveInsight’s comprehensive analysis revealing significant growth potential through 2034. The convergence of expanding patient populations, robust pipeline activity, and growing clinical evidence for broader therapeutic applications positions this market for sustained expansion. As regulatory approvals continue to validate the therapeutic potential of GLP-1 agonists and pharmaceutical companies advance innovative formulations through clinical development, stakeholders across the healthcare industry should closely monitor these developments to capitalize on the substantial opportunities emerging in this dynamic therapeutic landscape.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of GLP-1 Agonists
4. Key Events
5. GLP-1 Agonists Market Overview At A Glance
6. Background And Overview
7. GLP-1 Agonists Target Population
8. GLP-1 Agonists Marketed Drugs
9. GLP-1 Agonists Emerging Drugs
10. GLP-1 Agonists: The 7MM Analysis
11. GLP-1 Agonists Unmet Needs
12. SWOT Analysis
13. KOL Views
14. GLP-1 Agonists Market Access and Reimbursement
15. Appendix
16. Delveinsight Capabilities
17. Disclaimer
18. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: GLP-1 Drugs Market Outlook: Expanding Patient Pool, FDA Approvals, and Robust Pipeline Fuel Growth to 2034 | DelveInsight
